Myeloid Neoplasm Post Cytotoxic Therapy

Myeloid Neoplasm Post Cytotoxic Therapy — Trials · CancerIndex

Clinical trials

Registered studies

65 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 24.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–33 of 33 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04269213	CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old	completed	Phase 2	21	Roswell Park Cancer InstituteOTHER	1	Sep 8, 2026	clinicaltrials
NCT00093470	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission	completed	Phase 3	144	National Cancer Institute (NCI)NIH	3	Jul 14, 2026	clinicaltrials